Vitamin E Succinate Exerts Anti-tumour Effects on Human Cervical Cancer Cells Via the CD47-SIRPɑ Pathway Both and

Overview

Journal J Cancer

Specialty Oncology

Date 2021 Jun 7

PMID 34093795

Citations 6

Authors

Xiaoli Huang

Markus Neckenig

Jintang Sun

Di Jia

Yu Dou

Dan Ai

Zhaodi Nan

Xun Qu

Affiliations

Soon will be listed here.

Abstract

Vitamin E succinate (RRR-a-tocopheryl succinate, VES) acts as a potent agent for cancer therapy and has no toxic and side effects on normal tissue cells. However, the mechanism by which VES mediates the effects are not yet fully understood. Here, we hypothesised that VES mediates antitumour activity on human cervical cancer cells via the CD47-SIRPɑ pathway and . Results indicated that the human cervical cancer HeLa cells treated with VES were more efficiently engulfed by THP-1-derived macrophages. In response to VES, the protein expression of CD47 on cell membranes and the mRNA level of CD47 in different human cervical cancer cells significantly decreased. And the level of calreticulin (CRT) mRNA in the VES-treated cells increased. By contrast, CRT protein expression was not altered. miRNA-155, miRNA-133 and miRNA-326 were up-regulated in the VES-treated HeLa cells. Knocking down miRNA-155 and miRNA-133 by RNA interference increased CD47 protein expression in the VES-treated cells. efficacy was determined in BALB/C nude mice with HeLa xenografts. Results showed that VES reduced tumour growth, increased overall survival and inhibited CD47 in the tumour transcriptionally and translationally. Furthermore, inflammatory factors (TNF-α, IL-12, IFN-γ, IL-2 and IL-10) in the spleen were altered because of VES treatment. Our results suggest that VES-induced antitumour activity is coupled to the CD47-SIRPɑ pathway in human cervical HeLa cancer cells.

Citing Articles

Extracellular vesicles and macrophages in tumor microenvironment: Impact on cervical cancer.

Guo W, Liu W, Wang J, Fan X Heliyon. 2024; 10(15):e35063.

PMID: 39165926 PMC: 11334669. DOI: 10.1016/j.heliyon.2024.e35063.

Research Progress of SN38 Drug Delivery System in Cancer Treatment.

Qi Q, Tian H, Yue B, Zhai B, Zhao F Int J Nanomedicine. 2024; 19:945-964.

PMID: 38293612 PMC: 10826519. DOI: 10.2147/IJN.S435407.

The role of miR1 and miR133a in new-onset atrial fibrillation after acute myocardial infarction.

Zeng Q, Li W, Luo Z, Zhou H, Duan Z, Xiong X BMC Cardiovasc Disord. 2023; 23(1):448.

PMID: 37697243 PMC: 10496401. DOI: 10.1186/s12872-023-03462-x.

Bioinformatics Analysis of Novel Targets for Treating Cervical Cancer by Immunotherapy Based on Immune Escape.

Han Y, Ma D, Lee S, Mao Y, Sun S, Jin M Cancer Genomics Proteomics. 2023; 20(4):383-397.

PMID: 37400149 PMC: 10320560. DOI: 10.21873/cgp.20390.

Combination of Se-methylselenocysteine, D-α-tocopheryl succinate, β-carotene, and L-lysine can prevent cancer metastases using as an adjuvant therapy.

Cheng Y, Lian S, Li S, Lu Y, Wang J, Deng X J Zhejiang Univ Sci B. 2022; 23(11):943-956.

PMID: 36379613 PMC: 9676092. DOI: 10.1631/jzus.B2200232.

References

Navarathna D, Stein E, Lessey-Morillon E, Nayak D, Martin-Manso G, Roberts D . CD47 Promotes Protective Innate and Adaptive Immunity in a Mouse Model of Disseminated Candidiasis. PLoS One. 2015; 10(5):e0128220. PMC: 4444371. DOI: 10.1371/journal.pone.0128220. View

Tomasetti M, Neuzil J . Vitamin E analogues and immune response in cancer treatment. Vitam Horm. 2007; 76:463-91. DOI: 10.1016/S0083-6729(07)76018-1. View

Hou L, Zhang H, Xu P, Zhang L, Zhang X, Sun Y . Effect of vitamin E succinate on the expression of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor in gastric cancer cells and CD4(+) T cells. Mol Biosyst. 2015; 11(11):3119-28. DOI: 10.1039/c5mb00350d. View

de Almeida A, Barbosa S, de Lourdes Rios Barjas-Castro M, Olalla-Saad S, Condino-Neto A . IFN-β, IFN-γ, and TNF-α decrease erythrophagocytosis by human monocytes independent of SIRP-α or SHP-1 expression. Immunopharmacol Immunotoxicol. 2012; 34(6):1054-9. DOI: 10.3109/08923973.2012.697470. View

Huang Y, Ma Y, Gao P, Yao Z . Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy. J Thorac Dis. 2017; 9(2):E168-E174. PMC: 5334085. DOI: 10.21037/jtd.2017.02.30. View

Yu W, Sanders B, Kline K . Modulation of murine EL-4 thymic lymphoma cell proliferation and cytokine production by vitamin E succinate. Nutr Cancer. 1996; 25(2):137-49. DOI: 10.1080/01635589609514436. View

Vasques-Novoa F, Laundos T, Cerqueira R, Quina-Rodrigues C, Soares-Dos-Reis R, Baganha F . MicroRNA-155 Amplifies Nitric Oxide/cGMP Signaling and Impairs Vascular Angiotensin II Reactivity in Septic Shock. Crit Care Med. 2018; 46(9):e945-e954. DOI: 10.1097/CCM.0000000000003296. View

Angulo-Molina A, Reyes-Leyva J, Lopez-Malo A, Hernandez J . The role of alpha tocopheryl succinate (α-TOS) as a potential anticancer agent. Nutr Cancer. 2013; 66(2):167-76. DOI: 10.1080/01635581.2014.863367. View

Wu K, Shan Y, Zhao Y, Yu J, Liu B . Inhibitory effects of RRR-alpha-tocopheryl succinate on benzo(a)pyrene (B(a)P)-induced forestomach carcinogenesis in female mice. World J Gastroenterol. 2002; 7(1):60-5. PMC: 4688702. DOI: 10.3748/wjg.v7.i1.60. View

10.

Chao M, Alizadeh A, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F . Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 2010; 71(4):1374-84. PMC: 3041855. DOI: 10.1158/0008-5472.CAN-10-2238. View

11.

Schcolnik-Cabrera A, Oldak B, Juarez M, Cruz-Rivera M, Flisser A, Mendlovic F . Calreticulin in phagocytosis and cancer: opposite roles in immune response outcomes. Apoptosis. 2019; 24(3-4):245-255. DOI: 10.1007/s10495-019-01532-0. View

12.

Neuzil J, Weber T, Gellert N, Weber C . Selective cancer cell killing by alpha-tocopheryl succinate. Br J Cancer. 2001; 84(1):87-9. PMC: 2363620. DOI: 10.1054/bjoc.2000.1559. View

13.

Lian S, Xie R, Ye Y, Xie X, Li S, Lu Y . Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine. 2019; 42:281-295. PMC: 6491392. DOI: 10.1016/j.ebiom.2019.03.018. View

14.

Feng M, Chen J, Weissman-Tsukamoto R, Volkmer J, Ho P, McKenna K . Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci U S A. 2015; 112(7):2145-50. PMC: 4343163. DOI: 10.1073/pnas.1424907112. View

15.

Losuwannarak N, Maiuthed A, Kitkumthorn N, Leelahavanichkul A, Roytrakul S, Chanvorachote P . Gigantol Targets Cancer Stem Cells and Destabilizes Tumors via the Suppression of the PI3K/AKT and JAK/STAT Pathways in Ectopic Lung Cancer Xenografts. Cancers (Basel). 2019; 11(12). PMC: 6966687. DOI: 10.3390/cancers11122032. View

16.

Suzuki S, Yokobori T, Tanaka N, Sakai M, Sano A, Inose T . CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep. 2012; 28(2):465-72. DOI: 10.3892/or.2012.1831. View

17.

Li F, Lv B, Liu Y, Hua T, Han J, Sun C . Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells. Oncoimmunology. 2018; 7(2):e1391973. PMC: 5749673. DOI: 10.1080/2162402X.2017.1391973. View

18.

Malafa M, Fokum F, Mowlavi A, Abusief M, King M . Vitamin E inhibits melanoma growth in mice. Surgery. 2002; 131(1):85-91. DOI: 10.1067/msy.2002.119191. View

19.

Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout S . Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front Immunol. 2019; 9:2909. PMC: 6297829. DOI: 10.3389/fimmu.2018.02909. View

20.

Savitskaya M, Onischenko G . α-Tocopheryl Succinate Affects Malignant Cell Viability, Proliferation, and Differentiation. Biochemistry (Mosc). 2016; 81(8):806-18. DOI: 10.1134/S0006297916080034. View